BAYER AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 662
- Registration Number
- NCT04736199
- Locations
- 🇱🇹
National Cancer Institute, Vilnius, Lithuania
🇨🇳Nantong tumor hospital, Nantong, Jiangsu, China
🇨🇳The 2nd Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Trial to Learn How Much Rivaroxaban Gets Into the Blood When Taken in Different Forms and How Safe They Are in Healthy Men
- Conditions
- Healthy Volunteers
- Interventions
- Drug: 20 mg tablet rivaroxabanDrug: 20 mg rivaroxaban, granules for oral suspension
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 30
- Registration Number
- NCT04727021
- Locations
- 🇩🇪
CRS Clinical-Research-Services Mönchengladbach GmbH, Mönchengladbach, Nordrhein-Westfalen, Germany
A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy Participants
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 27
- Registration Number
- NCT04722562
A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Kidney Disease and in Age-, Weight- and Gender-matched Healthy Participants
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 39
- Registration Number
- NCT04722484
A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention.
- Conditions
- Non-Valvular Atrial Fibrillation
- Interventions
- Drug: Non-VKA Oral Anticoagulants (NOAC)
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 103
- Registration Number
- NCT04722679
- Locations
- 🇧🇪
Many Locations, Multiple Locations, Belgium
Non-proliferative Diabetic Retinopathy Treated With Runcaciguat
- Conditions
- Diabetic Retinopathy
- Interventions
- Other: Placebo
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 109
- Registration Number
- NCT04722991
- Locations
- 🇺🇸
Mid Atlantic Retina Specialists - Hagerstown, Hagerstown, Maryland, United States
🇺🇸Gulf Coast Eye Institute / Valley Retina Institute, McAllen, Texas, United States
🇨🇿Všeobecná fakultní nemocnice v Praze, Praha 2, Czechia
A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants
- Conditions
- Thromboembolic Disorders
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 30
- Registration Number
- NCT04720092
- Locations
- 🇩🇪
CRS Clinical-Research-Services Mönchengladbach GmbH, Mönchengladbach, Nordrhein-Westfalen, Germany
A Trial to Learn More About How Well BAY2586116 Works and How Safe it is in Participants With Moderate to Severe Obstructive Sleep Apnea
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 93
- Registration Number
- NCT04713826
- Locations
- 🇩🇪
Ruhrlandklinik, Westdeutsches Lungenzentrum, Essen, Nordrhein-Westfalen, Germany
🇩🇪Advanced Sleep Research GmbH, Berlin, Germany
🇨🇭UniversitätsSpital Zürich, Zürich, Switzerland
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- Drug: Regorafenib, (Stivarga, BAY73-4506)
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 175
- Registration Number
- NCT04704154
- Locations
- 🇯🇵
Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan
🇺🇸City of Hope - Duarte Cancer Center, Duarte, California, United States
🇺🇸Rocky Mountain Cancer Centers / Aurora, CO, Aurora, Colorado, United States
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 95
- Registration Number
- NCT04696055
- Locations
- 🇫🇷
Center Hospitalier Michallon - Grenoble, Grenoble Cedex 9, France
🇫🇷Hopital Claude Huriez - Lille, Lille, France
🇫🇷Hôpital de la Croix Rousse, Lyon, France